Published in Liver Int on August 11, 2011
Risk Factors for Renal Functional Decline in Chronic Hepatitis B Patients Receiving Oral Antiviral Agents. Medicine (Baltimore) (2016) 0.92
Association between adefovir dipivoxil treatment and the risk of renal insufficiency in patients with chronic hepatitis B: A meta-analysis. Biomed Rep (2015) 0.80
Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B. World J Gastroenterol (2015) 0.79
Prolonged Combination Therapy is More Effective than Monotherapy in Management of Chronic Hepatitis B Patients With Sustained Virological Response: An Experience From a 'Real-World' Clinical Setting. Iran Red Crescent Med J (2013) 0.78
Antiviral treatment for chronic hepatitis B in renal transplant patients. World J Hepatol (2015) 0.78
Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B: A meta-analysis. Medicine (Baltimore) (2016) 0.75
Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? Hepatology (2008) 1.81
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology (2010) 1.79
Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. Am J Gastroenterol (2003) 1.75
Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol (2004) 1.71
Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis. Eur J Gastroenterol Hepatol (2008) 1.62
Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl (2005) 1.58
Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology (2005) 1.46
Hepatic granulomas: a 6-year experience in a single center in Greece. Eur J Gastroenterol Hepatol (2007) 1.45
Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis (2006) 1.40
Targeting portal pressure measurements: a critical reappraisal. Hepatology (2004) 1.36
Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm (2009) 1.26
The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol (2006) 1.23
Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol (2010) 1.23
Adverse drug reactions as a cause of hospital admissions: a 6-month experience in a single center in Greece. Eur J Intern Med (2008) 1.15
Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl (2008) 1.14
Pseudohyperkalemia in serum: the phenomenon and its clinical magnitude. J Lab Clin Med (2006) 1.12
Acute liver failure as the initial manifestation of hepatic infiltration by a solid tumor: report of 5 cases and review of the literature. Tumori (2006) 1.11
Hepatic parenchyma resection using stapling devices: peri-operative and long-term outcome. HPB (Oxford) (2009) 1.03
TIPS for acute and chronic Budd-Chiari syndrome: a single-centre experience. J Hepatol (2003) 1.03
Hepatotoxicity induced by cyproterone acetate: a report of three cases. World J Gastroenterol (2006) 1.00
Increasing frequency of Gram-positive bacteria in spontaneous bacterial peritonitis. Liver Int (2005) 0.99
Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand J Gastroenterol (2008) 0.98
Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. J Clin Gastroenterol (2010) 0.97
Treatment of HBeAg-negative chronic hepatitis B. Semin Liver Dis (2003) 0.97
Does clinical response correlate with mucosal healing in patients with Crohn's disease of the small bowel? A prospective, case-series study using wireless capsule endoscopy. Inflamm Bowel Dis (2008) 0.97
Primary aortojejunal fistula due to foreign body: a rare cause of gastrointestinal bleeding. Eur J Gastroenterol Hepatol (2002) 0.94
Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial. Gastrointest Endosc (2002) 0.94
Aspartate aminotransferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis. Eur J Gastroenterol Hepatol (2006) 0.94
Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol (2008) 0.93
EASL clinical practice guidelines on the management of chronic hepatitis B: the need for liver biopsy. J Hepatol (2009) 0.93
Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C. Liver Int (2010) 0.91
Predicting utility of a model for end stage liver disease in alcoholic liver disease. World J Gastroenterol (2006) 0.91
Hepatic steatosis in genotype 4 chronic hepatitis C is mainly because of metabolic factors. Am J Gastroenterol (2007) 0.91
Sensorineural hearing loss complicating severe rickettsial diseases: report of two cases. J Infect (2007) 0.90
Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications. Scand J Gastroenterol (2009) 0.90
Ultrasound-guided liver biopsy in real life: comparison of same-day prebiopsy versus real-time ultrasound approach. J Gastroenterol Hepatol (2007) 0.89
Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension. J Hepatol (2009) 0.89
Hepatic venous pressure gradient to assess fibrosis and its progression after liver transplantation for HCV cirrhosis. Liver Transpl (2007) 0.88
Resistance issues in treating chronic hepatitis B. Future Microbiol (2008) 0.88
Assessment of blood coagulation in severe liver disease using thromboelastography: use of citrate storage versus native blood. Blood Coagul Fibrinolysis (2003) 0.88
Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J Hepatol (2010) 0.87
Current progress in the treatment of chronic hepatitis C. World J Gastroenterol (2012) 0.87
Smoking is associated with steatosis and severe fibrosis in chronic hepatitis C but not B. Scand J Gastroenterol (2009) 0.86
Serum HBV-DNA levels in inactive hepatitis B virus carriers. Gastroenterology (2002) 0.86
Aetiology and outcome of acute hepatic failure in Greece: experience of two academic hospital centres. Liver Int (2008) 0.86
Biliary tract malignancy and abnormal pancreaticobiliary junction in a Western population. J Gastroenterol Hepatol (2007) 0.85
Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation (2003) 0.85
HBeAg-negative chronic hepatitis B: from obscurity to prominence. J Hepatol (2006) 0.85
Hepatitis C virus genotyping in Greece: unexpected high prevalence of genotype 5a in a Greek island. J Med Virol (2012) 0.85
Pericarditis and possible antiphospholipid syndrome on primary biliary cirrhosis. Ann Hepatol (2005) 0.84
Angioimmunoblastic T-cell lymphoma-associated arthritis: case report and literature review. J Clin Rheumatol (2005) 0.84
Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial. Am J Gastroenterol (2002) 0.84
Painful peripheral neuropathy associated with voriconazole use. Arch Neurol (2005) 0.84
A fatal case of postinfantile giant cell hepatitis in a patient with chronic lymphocytic leukaemia. Eur J Gastroenterol Hepatol (2003) 0.83
Peginterferon-alpha2a (40 kDa) for chronic hepatitis C. Expert Opin Pharmacother (2003) 0.83
Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol (2007) 0.83
Treatment of hepatitis B in patients with chronic kidney disease. Kidney Int (2013) 0.83
An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study. BMC Gastroenterol (2007) 0.82
Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection. Expert Rev Anti Infect Ther (2004) 0.82
Hepatitis C virus survival curve analysis in naïve patients treated with peginterferon alpha-2b plus ribavirin. A randomized controlled trial for induction with high doses of peginterferon and predictability of sustained viral response from early virologic data. J Gastrointestin Liver Dis (2006) 0.81
Patient's age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin. Eur J Intern Med (2008) 0.81
Ursodeoxycholic acid and histological progression in primary biliary cirrhosis. J Hepatol (2003) 0.81
Precore mutant chronic hepatitis B - approach to management. MedGenMed (2003) 0.81
Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection. Curr Opin Investig Drugs (2010) 0.81
Serum gastrin levels in patients with inflammatory bowel disease. Hepatogastroenterology (2003) 0.81
Listeria monocytogenes peritonitis: presentation, clinical features, treatment, and outcome. Scand J Gastroenterol (2012) 0.80
Subacute thyroiditis presenting as fever of unknown origin in a patient with rheumatoid arthritis under etanercept treatment. J Clin Rheumatol (2010) 0.80
Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. World J Gastroenterol (2005) 0.80
Hepatitis C virus (HCV)-related cryoglobulinemia: cryoglobulin type and anti-HCV profile. Clin Vaccine Immunol (2013) 0.80
Immunogenicity of recombinant hepatitis B vaccine in treatment-naive and treatment-experienced chronic hepatitis C patients: the effect of pegylated interferon plus ribavirin treatment. World J Gastroenterol (2006) 0.80
Keratin 19 protein expression is an independent predictor of survival in human hepatocellular carcinoma. Eur J Gastroenterol Hepatol (2015) 0.80
Spontaneous bacterial peritonitis in cirrhotic patients: Is prophylactic propranolol therapy beneficial? J Gastroenterol Hepatol (2006) 0.79
Acute ischemic injury due to a giant intrahepatic hematoma: A complication of percutaneous liver biopsy. Eur J Intern Med (2007) 0.79
Combined HLA-DR and -DQ disparity is associated with a stable course of ulcerative colitis after liver transplantation for primary sclerosing cholangitis. Liver Transpl (2007) 0.79
Changes of serum levels of keratin-18 fragments in hepatitis B e antigen-negative chronic hepatitis B patients under oral antiviral therapy. Antivir Ther (2011) 0.79
Treatment of HBeAg negative chronic hepatitis B with new drugs (adefovir and others). J Hepatol (2003) 0.78
The burden and recent epidemiological changes of the main chronic liver diseases in a Greek referral tertiary centre. Eur J Gastroenterol Hepatol (2010) 0.78
On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients. Liver Int (2014) 0.78
Increased abdominal fat levels measured by bioelectrical impedance are associated with histological lesions of nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol (2015) 0.78
Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients? Liver Int (2015) 0.78
Cholestasis in acute stroke: an investigation on its prevalence and etiology. Scand J Gastroenterol (2005) 0.78
Cytokeratin 8 and 18 expression in imprint smears of chronic viral hepatitis, autoimmune hepatitis and hepatocellular carcinoma. A preliminary study. Acta Cytol (2007) 0.78
Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter? J Med Virol (2012) 0.78
Serological profile of HBV infection and liver histopathology among injecting drug users with chronic HCV infection in Greece. Eur J Intern Med (2005) 0.77
HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa? Liver Int (2014) 0.77
Frequency and predictors of no treatment in anti-hepatitis C virus-positive patients at tertiary liver centers in Greece. Eur J Gastroenterol Hepatol (2013) 0.77
Prevention of variceal rebleeding. Lancet (2003) 0.77
Liver involvement in acute vaso-occlusive crisis of sickle cell disease: prevalence and predisposing factors. Scand J Gastroenterol (2007) 0.77